Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
PR Newswire —
NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products Administration (NMPA) Center for Drug Evaluation...